Absence of interleukin-17 receptor a signaling prevents autoimmune inflammation of the joint and leads to a Th2-like phenotype in collagen-induced arthritis

Arthritis and Rheumatology

Volumn 66, Issue 2, 2014, Pages 340-349

  Corneth, Odilia B J ^a   Mus, Adriana M C ^a   Asmawidjaja, Patrick S ^a   Wolterink, Roel G J K ^a   Van Nimwegen, Menno ^a   Brem, Maarten D ^a   Hofman, Yara ^a   Hendriks, Rudi W ^a   Lubberts, Erik ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2C; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17 RECEPTOR A; INTERLEUKIN 23P19; INTERLEUKIN 4; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FIBROBLAST; HELPER CELL; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MORBIDITY; MOUSE; NONHUMAN; PATHOGENICITY; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SPLEEN CELL; SYNOVIOCYTE; SYNOVITIS; TH2 CELL; WILD TYPE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKIN-4; JOINTS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; PLASMA CELLS; RECEPTORS, INTERLEUKIN-17; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TH2 CELLS;

EID: 84896287860     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38229     Document Type: Article

References (50)

1. Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol 2011;23: 613-9.
2. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011;34: 149-62.
3. Dubin PJ, Kolls JK. Th17 cytokines and mucosal immunity. Immunol Rev 2008;226: 160-71.
4. Curtis MM, Way SS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 2009; 126: 177-85.
5. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, et al. Interleukin 17 acts in synergy with B cellactivating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009;10: 778-85.
6. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, et al. Interleukin-17 production in central nervous systeminfiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172: 146-55.
7. Venken K, Hellings N, Hensen K, Rummens JL, Stinissen P. Memory CD4-CD127high T cells from patients with multiple sclerosis produce IL-17 in response to myelin antigens. J Neuroimmunol 2010;226: 185-91.
8. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin- 17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72.
9. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998;161: 409-14.
10. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010;62: 2876-85.
11. Pisitkun P, Ha HL, Wang H, Claudio E, Tivy CC, Zhou H, et al. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 2012;37: 1104-15.
12. Starnes T, Robertson MJ, Sledge G, Kelich S, Nakshatri H, Broxmeyer HE, et al. IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol 2001;167: 4137-40.
13. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 2001;20: 5332-41.
14. Takatori H, Kanno Y, Watford WT, Tato CM, Weiss G, Ivanov, II, et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 2009;206: 35-41.
15. Passos ST, Silver JS, O'Hara AC, Sehy D, Stumhofer JS, Hunter CA. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J Immunol 2010;184: 1776-83.
16. Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB, et al. Identification of an IL-17-producing NK1.1neg iNKT cell population involved in airway neutrophilia. J Exp Med 2007;204: 995-1001.
17. Takahashi N, Vanlaere I, de Rycke R, Cauwels A, Joosten LA, Lubberts E, et al. IL-17 produced by Paneth cells drives TNFinduced shock. J Exp Med 2008;205: 1755-61.
18. Liang SC, Long AJ, Bennett F, Whitters MJ, Karim R, Collins M, et al. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 2007;179: 7791-9.
19. Wright JF, Guo Y, Quazi A, Luxenberg DP, Bennett F, Ross JF, et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4- T cells. J Biol Chem 2007;282: 13447-55.
20. Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res 2007;17: 435-40.
21. Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum K, et al. Identification of the IL-17 receptor related molecule IL- 17RC as the receptor for IL-17F. J Immunol 2007;179: 5462-73.
22. Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J, et al. Interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006;177: 36-9.
23. Ho AW, Gaffen SL. IL-17RC: a partner in IL-17 signaling and beyond. Semin Immunopathol 2010;32: 33-42.
24. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009;30: 108-19.
25. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995; 3: 811-21.
26. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009;9: 556-67.
27. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 2008;41: 84-91.
28. Van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes JM, et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011;63: 73-83.
29. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010;62: 929-39.
30. Yamaguchi Y, Fujio K, Shoda H, Okamoto A, Tsuno NH, Takahashi K, et al. IL-17B and IL-17C are associated with TNF - production and contribute to the exacerbation of inflammatory arthritis. J Immunol 2007;179: 7128-36.
31. Shi Y, Ullrich SJ, Zhang J, Connolly K, Grzegorzewski KJ, Barber MC, et al. A novel cytokine receptor-ligand pair: identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 2000;275: 19167-76.
32. Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez GJ, Dong C. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 2011;35: 611-21.
33. Rickel EA, Siegel LA, Yoon BR, Rottman JB, Kugler DG, Swart DA, et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol 2008; 181: 4299-310.
34. Kim MR, Manoukian R, Yeh R, Silbiger SM, Danilenko DM, Scully S, et al. Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood 2002;100: 2330-40.
35. Pan G, French D, Mao W, Maruoka M, Risser P, Lee J, et al. Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice. J Immunol 2001;167: 6559-67.
36. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 2001;15: 985-95.
37. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171: 6173-7.
38. Pisitkun P, Claudio E, Ren N, Wang H, Siebenlist U. The adaptor protein CIKS/ACT1 is necessary for collagen-induced arthritis, and it contributes to the production of collagen-specific antibody. Arthritis Rheum 2010;62: 3334-44.
39. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001;194: 519-27.
40. Ghilardi N, Kljavin N, Chen Q, Lucas S, Gurney AL, de Sauvage FJ. Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J Immunol 2004;172: 2827-33.
41. Van Hamburg JP, Mus AM, de Bruijn MJ, de Vogel L, Boon L, Cornelissen F, et al. GATA-3 protects against severe joint inflammation and bone erosion and reduces differentiation of Th17 cells during experimental arthritis. Arthritis Rheum 2009;60: 750-9.
42. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen- de Roo CJ, Kolls JK, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001;167: 1004-13.
43. GeurtsvanKessel CH, Willart MA, Bergen IM, van Rijt LS, Muskens F, Elewaut D, et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J Exp Med 2009;206: 2339-49.
44. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198: 1951-7.
45. Svensson L, Jirholt J, Holmdahl R, Jansson L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol 1998;111: 521-6.
46. Lubberts E, Schwarzenberger P, Huang W, Schurr JR, Peschon JJ, van den Berg WB, et al. Requirement of IL-17 receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis. J Immunol 2005;175: 3360-8.
47. Joosten LA, Radstake TR, Lubberts E, van den Bersselaar LA, van Riel PL, van Lent PL, et al. Association of interleukin-18 expression with enhanced levels of both interleukin-1- and tumor necrosis factor - in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 2003;48: 339-47.
48. Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin- 4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997;40: 249-60.
49. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366: 1181-9.
50. Pavelka K, Chon Y, Newmark R, Erondu N, Lin SL. A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate [abstract]. Arthritis Rheum 2012; 64 Suppl:S362.